Clinical Trial

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Study acronym: PREFER
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to compare the efficacy and safety of BCD-178 and Perjeta as neoadjuvant therapy for HER2-positive breast cancer. Subjects with histologically confirmed diagnosis of HER2-positive invasive breast cancer (stage II-III, tumor size \> 2 cm), with no estrogen (ER) and progesterone (PR) receptors will be randomized to one of two treatment groups (BCD-178 group or Perjeta group) in a 1:1 ratio.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-05; most recent amendment 2025-07-17.
Status change: Recruiting → Active, Not Recruiting 2025-07-17
Trial Details
NCT Number NCT05802225
Lead Sponsor Biocad
Conditions Breast Cancer
Enrollment 398 participants
Start Date 2023-01-30
Primary Completion 2025-06-06 (estimated)
Study Completion 2026-02-20 (estimated)
Updated on ClinicalTrials.gov 2025-07-20